Clinical Trials Browser

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT02130466 2022-08-01

MK-3475-022

Phase 1/2 Completed

184 enrolled 62 charts

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT01336634 2022-04-04

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Phase 2 Completed

177 enrolled 19 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02083354 2022-02-01

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

Phase 2 Completed

77 enrolled 43 charts

Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

NCT01677741 2021-11-24

A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

Phase 1/2 Completed

85 enrolled 25 charts

CNS

Brain Neoplasms

NCT02974803 2021-08-20

Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases

Phase 2 Terminated

6 enrolled 3 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01584648 2021-02-17

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Phase 3 Completed

423 enrolled 15 charts

Dermatologic

Melanoma

NCT01682213 2020-05-26

Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

Phase 2 Completed

23 enrolled 10 charts

Dermatologic

Melanoma

NCT01072175 2019-07-05

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

Phase 2 Completed

430 enrolled 61 charts

Dermatologic

Melanoma, Neoplasms

NCT02039947 2019-05-21

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Phase 2 Completed

127 enrolled 17 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02314143 2019-02-18

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

Phase 2 Terminated

48 enrolled 20 charts

Dermatologic

Melanoma, Neoplasms

NCT01978236 2018-08-17

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

Phase 2 Terminated

6 enrolled 9 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01721603 2018-01-23

Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets

Phase 2 Terminated

2 enrolled 7 charts

Dermatologic

Melanoma

NCT01227889 2017-10-04

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Phase 3 Completed

251 enrolled 21 charts

Dermatologic

Melanoma, Neoplasms

NCT01153763 2017-09-27

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma

Phase 2 Completed

92 enrolled 22 charts

Dermatologic

Melanoma

NCT01928940 2017-07-24

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

Phase 2 Completed

12 enrolled 28 charts

Dermatologic

Melanoma

NCT01701037 2017-06-23

Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

Phase 2 Terminated

13 enrolled 13 charts

Dermatologic

Melanoma

NCT01534897 2017-03-15

Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436

Phase NA Completed

10 enrolled 9 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Neoplasm Metastasis, Thyroid Neoplasms

NCT01619774 2016-12-12

An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor

Phase 2 Completed

28 enrolled 7 charts

Dermatologic

Melanoma